Filtered By:
Drug: Yervoy
This page shows you your search results in order of date.
Order by Relevance | Date
Total 1151 results found since Jan 2013.
Treatment management for < em > BRAF < /em > -mutant melanoma patients with tumor recurrence on adjuvant therapy: a multicenter study from the prospective skin cancer registry ADOREG
CONCLUSIONS: BRAFmut melanoma patients who developed DM upon upfront adjuvant therapy achieve favorable tumor control and prolonged PFS after switching treatment modalities in the first-line setting of stage IV disease. Patients with locoregional recurrence benefit from complete resection of recurrence followed by a second adjuvant treatment with TT.PMID:37730278 | DOI:10.1136/jitc-2023-007630
Source: Cancer Control - September 20, 2023 Category: Cancer & Oncology Authors: Maximilian Haist Henner Stege Friederike Rogall Yuqi Tan Imke von Wasielewski Kai Christian Klespe Friedegund Meier Peter Mohr Katharina C K ähler Michael Weichenthal Axel Hauschild Dirk Schadendorf Selma Ugurel Georg Lodde Lisa Zimmer Ralf Gutzmer Dirk Source Type: research
EDIL3 as an angiogenic target of immune exclusion following checkpoint blockade
Cancer Immunol Res. 2023 Sep 20. doi: 10.1158/2326-6066.CIR-23-0171. Online ahead of print.ABSTRACTImmune checkpoint blockade (ICB) has become the standard of care for several solid tumors. Multiple combinatorial approaches have been studied to improve therapeutic efficacy. The combination of anti-angiogenesis agents and ICB has demonstrated efficacy in several cancers. To improve the mechanistic understanding of synergies with these treatment modalities, we performed serologic screens of human protein array using sera from long-term responding patients treated with ipilimumab and bevacizumab. We discovered a high-titer an...
Source: Cell Research - September 20, 2023 Category: Cytology Authors: Saba Tabasum Dinesh Thapa Anita Giobbie-Hurder Jason L Weirather Marco Campisi Pieter J Schol Xiaoyu Li Jingjing Li Charles H Yoon Michael P Manos David A Barbie F Stephen Hodi Source Type: research
Clinical utility of inflammatory and nutritious index as therapeutic prediction of nivolumab plus ipilimumab in advanced NSCLC
CONCLUSION: The NLR, PLR, SII, PNI, ALI, and GPS were significantly associated with the outcome of Nivo-Ipi treatment in patients with NSCLC. The PNI was the most suitable marker regardless of histological type. The SII and PNI were the most promising markers for patients with and without PD-L1 expression, respectively.PMID:37725914 | DOI:10.1159/000534169
Source: Oncology - September 19, 2023 Category: Cancer & Oncology Authors: Ou Yamaguchi Kyoichi Kaira Hisao Imai Atsuto Mouri Ayako Shiono Yu Miura Kosuke Hashimoto Kunihiko Kobayashi Hiroshi Kagamu Source Type: research
Real-world clinical outcomes of patients with metastatic renal cell carcinoma receiving pembrolizumab + axitinib vs. ipilimumab + nivolumab
CONCLUSIONS: Our study provides insight into newer mccRCC treatment tolerability and effectiveness in the real-world US community setting. Our real-world results were comparable to data from clinical trials, which is encouraging for mccRCC patients.PMID:37722984 | DOI:10.1016/j.urolonc.2023.08.009
Source: Urologic Oncology - September 18, 2023 Category: Urology & Nephrology Authors: Neil J Shah Sneha D Sura Reshma Shinde Junxin Shi Puneet Singhal Rodolfo F Perini Robert J Motzer Source Type: research
Correction to: First-line nivolumab plus ipilimumab in metastatic non-small cell lung cancer: 5-year outcomes in Japanese patients from CheckMate 227 Part 1
Int J Clin Oncol. 2023 Sep 9. doi: 10.1007/s10147-023-02408-9. Online ahead of print.NO ABSTRACTPMID:37684530 | DOI:10.1007/s10147-023-02408-9
Source: Clinical Lung Cancer - September 8, 2023 Category: Cancer & Oncology Authors: Makoto Nishio Yuichiro Ohe Satoshi Ikeda Toshihide Yokoyama Hidetoshi Hayashi Tatsuro Fukuhara Yuki Sato Hiroshi Tanaka Katsuyuki Hotta Shunichi Sugawara Haruko Daga Isamu Okamoto Kazuo Kasahara Tateaki Naito Li Li Ravi G Gupta Judith Bushong Hideaki Mizu Source Type: research
Immune checkpoint inhibitor therapy in neoadjuvant and adjuvant treatment for cancer: A paradigm shift in the treatment of resectable gastrointestinal cancer 3)A paradigm shift in the treatment of colorectal cancer
Int J Clin Oncol. 2023 Sep 5. doi: 10.1007/s10147-023-02387-x. Online ahead of print.ABSTRACTImmune checkpoint inhibitors, such as anti-programmed cell death-1, programmed cell death ligand-1, and cytotoxic T-lymphocyte antigen-4 monoclonal antibodies, have been notably effective in various types of cancers. Mismatch repair deficiency and microsatellite instability-high tumors have been established as striking biomarkers for response to immune checkpoint inhibitors. These biomarkers show a higher mutational burden, have cancer-associated neoantigens, and dense immune cell infiltration, which generates a robust immune respo...
Source: Clinical Colorectal Cancer - September 5, 2023 Category: Cancer & Oncology Authors: Kotoe Oshima Kentaro Yamazaki Source Type: research
High incidence of cytokine-release syndrome in patients with advanced NSCLC treated with nivolumab plus ipilimumab
Ann Oncol. 2023 Sep 2:S0923-7534(23)00827-X. doi: 10.1016/j.annonc.2023.08.012. Online ahead of print.NO ABSTRACTPMID:37666485 | DOI:10.1016/j.annonc.2023.08.012
Source: Ann Oncol - September 4, 2023 Category: Cancer & Oncology Authors: Y Shiraishi Y Sekino H Horinouchi Y Ohe I Okamoto Source Type: research
Combination Treatment of Intratumoral Vidutolimod, Radiosurgery, Nivolumab, and Ipilimumab for Microsatellite Stable Colorectal Carcinoma With Liver Metastases
CONCLUSIONS: The combination of intratumoral vidutolimod, radiosurgery, nivolumab and ipilimumab was not found to be efficacious in MSS mCRC with liver metastases. The juxtaposition of liver irradiation and intratumoral vidutolimod injection was associated with high hepatic toxicity.PMID:37657954 | DOI:10.1016/j.clcc.2023.08.004
Source: Clinical Colorectal Cancer - September 1, 2023 Category: Cancer & Oncology Authors: Ofer Margalit Sivan Lieberman Ilanit Redinsky Sharon Halparin Nir Honig Stephen Raskin Maoz Ben-Ayun Einat Shacham-Shmueli Naama Halpern Damien Urban Aliza Ackerstein Katerina Shulman Eytan Ben-Ami Valeriya Semenisty Ofer Purim Nirit Yarom Talia Golan Ben Source Type: research
Re-immunotherapy with nivolumab plus ipilimumab in advanced non-small cell lung cancer patients previously treated with anti-programmed death-1 and/or anti-programmed death ligand-1 antibodies
CONCLUSION: Re-immunotherapy with nivolumab plus ipilimumab after anti-PD-1 and/or anti-PD-L1 immunotherapy may be feasible and provide clinical benefit in selected patients. Further prospective studies are warranted to identify the patient population that may benefit from re-immunotherapy.PMID:37653078 | DOI:10.1007/s12672-023-00781-5
Source: Cancer Control - August 31, 2023 Category: Cancer & Oncology Authors: Takuma Imakita Kohei Fujita Takanori Ito Zentaro Saito Issei Oi Osamu Kanai Hiromasa Tachibana Satoru Sawai Tadashi Mio Source Type: research
A Pilot Study of Neoadjuvant Nivolumab, Ipilimumab, and Intralesional Oncolytic Virotherapy for HER2-negative Breast Cancer
CONCLUSIONS: This triple immunotherapy regimen provided responses in patients with advanced or relapsed HER2-negative breast cancer, at the expense of long-term toxicities.SIGNIFICANCE: Systemic immune checkpoint blockade with a programmed death receptor 1 and a CTL antigen-4 blocking antibody, combined with intralesional oncolytic virotherapy, is a chemotherapy-free combination aimed at inducing an antitumor immune response locally and systemic immunity.PMID:37621406 | PMC:PMC10445661 | DOI:10.1158/2767-9764.CRC-23-0145
Source: Cell Research - August 25, 2023 Category: Cytology Authors: Vina P Nguyen Katie M Campbell Theodore S Nowicki Nila Elumalai Egmidio Medina Ignacio Baselga-Carretero Maggie L DiNome Helena R Chang Denise K Oseguera Antoni Ribas John A Glaspy Source Type: research
